BG106193A - Използване на антитела срещу cd20 за лечение на заболявания при трансплантации - Google Patents

Използване на антитела срещу cd20 за лечение на заболявания при трансплантации Download PDF

Info

Publication number
BG106193A
BG106193A BG106193A BG10619301A BG106193A BG 106193 A BG106193 A BG 106193A BG 106193 A BG106193 A BG 106193A BG 10619301 A BG10619301 A BG 10619301A BG 106193 A BG106193 A BG 106193A
Authority
BG
Bulgaria
Prior art keywords
lymphocytes
human
antigen
cells
antibodies against
Prior art date
Application number
BG106193A
Other languages
Bulgarian (bg)
English (en)
Inventor
Josee Golay
Martino Introna
Alessandro Rambaldi
Andrea Biondi
Original Assignee
Consiglio Nazionale Delle Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Delle Ricerche filed Critical Consiglio Nazionale Delle Ricerche
Publication of BG106193A publication Critical patent/BG106193A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BG106193A 1999-06-11 2001-12-07 Използване на антитела срещу cd20 за лечение на заболявания при трансплантации BG106193A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001299A ITMI991299A1 (it) 1999-06-11 1999-06-11 Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
PCT/EP2000/005212 WO2000076542A1 (en) 1999-06-11 2000-06-07 Use of antibodies against cd20 for the treatment of the graft versus host disease

Publications (1)

Publication Number Publication Date
BG106193A true BG106193A (bg) 2002-08-30

Family

ID=11383150

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106193A BG106193A (bg) 1999-06-11 2001-12-07 Използване на антитела срещу cd20 за лечение на заболявания при трансплантации

Country Status (26)

Country Link
US (1) US20070014785A1 (cs)
EP (1) EP1185299B1 (cs)
JP (1) JP2003501482A (cs)
KR (1) KR20020026455A (cs)
CN (1) CN1253208C (cs)
AU (1) AU774206B2 (cs)
BG (1) BG106193A (cs)
CA (1) CA2376288A1 (cs)
CZ (1) CZ20014450A3 (cs)
DE (1) DE60033030T2 (cs)
DK (1) DK1185299T3 (cs)
EE (1) EE200100667A (cs)
ES (1) ES2278616T3 (cs)
HK (1) HK1043549B (cs)
HU (1) HUP0201600A3 (cs)
IL (1) IL146934A0 (cs)
IS (1) IS6195A (cs)
IT (1) ITMI991299A1 (cs)
NO (1) NO20016035L (cs)
NZ (1) NZ515992A (cs)
PL (1) PL352860A1 (cs)
PT (1) PT1185299E (cs)
SK (1) SK18132001A3 (cs)
TR (1) TR200103581T2 (cs)
WO (1) WO2000076542A1 (cs)
ZA (1) ZA200110004B (cs)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
CN1316019C (zh) * 2002-12-26 2007-05-16 中国医学科学院中国协和医科大学血液学研究所血液病医院 抗cd20嵌合抗体突变体基因及其应用
WO2004091657A2 (en) 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AU2004252067B2 (en) 2003-05-09 2012-04-12 Duke University CD20-specific antibodies and methods of employing same
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
US8530187B2 (en) * 2004-03-22 2013-09-10 The Ohio State University Research Foundation Methods for transfecting natural killer cells
KR20150092374A (ko) 2004-06-04 2015-08-12 제넨테크, 인크. 다발성 경화증의 치료 방법
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
AU2006251647A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
CN101008291B (zh) * 2006-01-26 2010-05-12 金海产品有限公司 用于水池清洁机的密封盒装置
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
WO2009001545A1 (ja) 2007-06-22 2008-12-31 Sapporo Medical University 移植片対宿主疾患の検査および治療方法
HUE037633T2 (hu) 2007-07-09 2018-09-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
MY147651A (en) 2007-07-31 2012-12-31 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
AU2008312406B2 (en) 2007-10-16 2014-03-06 Ares Trading S.A. Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US8568709B2 (en) 2008-03-20 2013-10-29 University Health Network Thymidylate kinase fusions and uses thereof
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
SG10201901417UA (en) 2009-08-11 2019-03-28 Genentech Inc Production of proteins in glutamine-free cell culture media
CN105001334A (zh) 2010-02-10 2015-10-28 伊缪诺金公司 Cd20抗体及其用途
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU719930B2 (en) * 1996-05-31 2000-05-18 Genetic Therapy, Inc. Prevention of graft-versus-host disease with T-cells including polynucleotides encoding negative selective markers
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses

Also Published As

Publication number Publication date
HK1043549B (zh) 2006-09-01
CN1355712A (zh) 2002-06-26
HK1043549A1 (en) 2002-09-20
WO2000076542A1 (en) 2000-12-21
DK1185299T3 (da) 2007-05-21
EP1185299A1 (en) 2002-03-13
NO20016035D0 (no) 2001-12-10
JP2003501482A (ja) 2003-01-14
IL146934A0 (en) 2002-08-14
EE200100667A (et) 2003-02-17
HUP0201600A2 (en) 2002-08-28
EP1185299B1 (en) 2007-01-17
PL352860A1 (en) 2003-09-08
PT1185299E (pt) 2007-03-30
HUP0201600A3 (en) 2005-04-28
SK18132001A3 (sk) 2002-05-09
CA2376288A1 (en) 2000-12-21
NO20016035L (no) 2002-02-11
IS6195A (is) 2001-12-10
CN1253208C (zh) 2006-04-26
ITMI991299A1 (it) 2000-12-11
TR200103581T2 (tr) 2002-08-21
ZA200110004B (en) 2003-02-26
AU5530300A (en) 2001-01-02
DE60033030D1 (de) 2007-03-08
ITMI991299A0 (it) 1999-06-11
CZ20014450A3 (cs) 2002-04-17
DE60033030T2 (de) 2007-05-31
ES2278616T3 (es) 2007-08-16
KR20020026455A (ko) 2002-04-10
AU774206B2 (en) 2004-06-17
US20070014785A1 (en) 2007-01-18
NZ515992A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
BG106193A (bg) Използване на антитела срещу cd20 за лечение на заболявания при трансплантации
Rosenzweig et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34+ hematopoietic cells
Serafini et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease
Donahue et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.
US5470730A (en) Method for producing TH -independent cytotoxic T lymphocytes
JP2001505043A (ja) 遺伝子導入
Berger et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model
JP2021502094A (ja) 閉鎖系極低温容器
EP1188825A1 (en) T cell receptor transfer into a candidate effector cell or a precursor thereof
Verhoeyen et al. Lentiviral vector gene transfer into human T cells
Kang et al. Induction of central deletional T cell tolerance by gene therapy
Hagani et al. Activation conditions determine susceptibility of murine primary T‐lymphocytes to retroviral infection
Burt et al. Herpes simplex thymidine kinase gene–transduced donor lymphocyte infusions
Maslennikova et al. Engineering T-cell resistance to HIV-1 infection via knock-in of peptides from the heptad repeat 2 domain of gp41
Clay et al. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer
Introna et al. Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells
JP2002501375A (ja) ワクチン評価のための動物モデル
Donahue et al. High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells
Engel et al. Stem cell directed gene therapy
Poznansky et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
CN114269356A (zh) 诱导细胞免疫和体液免疫的基于同种异体t细胞的hiv疫苗
JP2004523202A (ja) 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
EP0904786B1 (en) Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction
Schejtman Borisonik Lentiviral gene therapy for p47-deficient Chronic Granulomatous disease
Naranjo-Gomez et al. Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy. Vaccines 2021, 9, 137